Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    granules-india-limited-m-2025-07-07

    Virtual Booth

    Contact Supplier

    Allsino Pharma excels in R&D & manufacturing of RSMs, GMP intermediates, & APIs; ISO-certified, GMP-compliant, accredited by NMPA.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Orismilast

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Union Presents Orismilast Ph 2a In Ulcerative Colitis At ECCO 2025
    Union Presents Orismilast Ph 2a In Ulcerative Colitis At ECCO 2025

    21 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/union-therapeutics-announces-presentation-of-preliminary-data-from-phase-2a-investigator-initiated-study-with-orismilast-in-ulcerative-colitis-at-the-20th-ecco-congress-302382223.html

    PR NEWSWIRE
    21 Feb 2025
    Share Share
    UNION Announces ADESOS Phase 2b Results For Orismilast
    UNION Announces ADESOS Phase 2b Results For Orismilast

    25 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/union-therapeutics-announce-results-from-the-adesos-phase-2b-study-in-atopic-dermatitis-confirming-the-potential-of-orismilast-as-a-first-in-class-safe-and-efficacious-oral-treatment-302258828.html

    PR NEWSWIRE
    25 Sep 2024
    Share Share
    UNION to present orismilast Phase 2b results in atopic dermatitis
    UNION to present orismilast Phase 2b results in atopic dermatitis

    20 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/union-therapeutics-to-present-orismilast-phase-2b-results-in-atopic-dermatitis-as-a-late-breaking-oral-presentation-at-the-eadv-congress-2024-302254060.html

    PR NEWSWIRE
    20 Sep 2024
    Share Share
    UNION: ADESOS Phase 2b Success, Data At RAVE Conference 2024
    UNION: ADESOS Phase 2b Success, Data At RAVE Conference 2024

    04 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/union-therapeutics-announces-successful-completion-of-the-adesos-phase-2b-study-and-presentation-of-data-at-the-rave-conference-2024-302162871.html

    PR NEWSWIRE
    04 Jun 2024
    Share Share
    UNION therapeutics announces presentation of new data on orismilast
    UNION therapeutics announces presentation of new data on orismilast

    06 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/union-therapeutics-announces-presentation-of-new-data-on-orismilast-at-the-eadv-congress-2023-301949287.html

    PR NEWSWIRE
    06 Oct 2023
    Share Share
    US FDA grants Fast Track status for UNION’s oral orismilast to treat HS
    US FDA grants Fast Track status for UNION’s oral orismilast to treat HS

    11 Jan 2023

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/fda-union-oral-orismilast-hs/

    PHARMACEUTICAL-TECHNOLOGY
    11 Jan 2023
    Share Share